Pharvaris (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan Sells 800 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 800 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $36.19, for a total transaction of $28,952.00. Following the sale, the director directly owned 115,167 shares in the company, valued at $4,167,893.73. This trade represents a 0.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Thursday, September 17th, Johannes Gerardus Chri Schikan sold 200,000 shares of Pharvaris stock. The shares were sold at an average price of $35.00, for a total transaction of $7,000,000.00.
• On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88.
• On Monday, June 29th, Johannes Gerardus Chri Schikan sold 6,888 shares of Pharvaris stock. The stock was sold at an average price of $35.05, for a total value of $241,424.40.

Pharvaris Price Performance

Shares of Pharvaris stock traded down $0.52 during trading hours on Thursday, hitting $32.55. The company’s stock had a trading volume of 201,154 shares, compared to its average volume of 413,337. Pharvaris N.V. has a 12 month low of $20.65 and a 12 month high of $43.25. The stock has a 50 day moving average of $35.36 and a 200 day moving average of $31.93. The company has a market capitalization of $2.13 billion, a PE ratio of -10.67 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Equities analysts expect that Pharvaris N.V. will post -3.12 EPS for the current year.

Institutional Trading of Pharvaris

Several hedge funds and other institutional investors have recently made changes to their positions in PHVS. Engineers Gate Manager LP bought a new position in shares of Pharvaris during the second quarter valued at $1,143,000. Amundi raised its stake in Pharvaris by 61.4% during the second quarter. Amundi now owns 49,944 shares of the company’s stock worth $1,727,000 after buying an additional 18,992 shares during the last quarter. Moore Capital Management LP acquired a new stake in Pharvaris during the 2nd quarter worth about $1,522,000. Alyeska Investment Group L.P. grew its stake in Pharvaris by 225.5% during the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock worth $14,068,000 after purchasing an additional 281,829 shares during the period. Finally, Wellington Management Group LLP increased its holdings in Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after purchasing an additional 274,034 shares in the last quarter.

Analysts Set New Price Targets

PHVS has been the topic of several analyst reports. UBS Group set a $79.00 price target on shares of Pharvaris in a research report on Wednesday, September 9th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a research report on Wednesday, September 9th. Oppenheimer reissued an “outperform” rating and set a $75.00 price target on shares of Pharvaris in a research report on Tuesday, September 8th. Wells Fargo & Company boosted their target price on shares of Pharvaris from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Finally, Royal Bank Of Canada lifted their target price on shares of Pharvaris from $52.00 to $62.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $59.87.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.